Highest-materiality recent filing
Medicus Pharma receives Nasdaq bid price deficiency notice; expands ATM to $50M
Nasdaq notified Medicus on April 21, 2026 that its stock bid price closed below $1.00 for 30 consecutive business days, non-compliant with Listing Rule 5550(a)(2).
Medicus Pharma enters $5.1M warrant inducement; issues new warrants for 4M shares
Gross proceeds ~$5.1M from exercise of 2,680,000 existing warrants at amended price of $1.92/share.
Medicus Pharma appoints Carolyn Bonner as CFO; Jim Quinlan resigns for health reasons
James Quinlan resigned as CFO effective Nov 28, 2025, after medical leave since Sep 12, 2025.
Medicus Pharma Q3 net loss $16M, pipeline advances with SkinJect and Teverelix
Net loss $16.0M in Q3 2025 vs $2.3M in Q3 2024; R&D $1.7M, G&A $5.0M.
Medicus Pharma secures $8M non-dilutive debenture from Yorkville; net proceeds $5.7M
$8M principal, 8% interest, matures Sept 2026; monthly installments of $650k plus accrued interest.
Medicus Pharma completes Antev acquisition for ~$3M cash + 1.6M shares; up to $65M contingent
Acquired 98.6% of Antev for ~$3.0M cash and 1,603,164 MDCX shares; up to $65M in contingent milestones tied to FDA Phase 2 and NDA approvals.
Medicus Pharma: FDA accepts Type C meeting; Phase 2 BCC study >75% randomized; Q2 net loss $6.2M
FDA accepted Type C meeting request; written queries submitted, response expected before end of Q3 2025.
Medicus Pharma hires Deloitte to find out-licensing partner for D-MNA (BCC)
Deloitte appointed exclusive lead financial adviser for out-licensing D-MNA for basal cell carcinoma.
Medicus Pharma enters warrant inducement for $3.75M gross; also sells $1.52M shares via SEPA
Holder exercises 1.34M existing warrants at $2.80; receives 2.68M new warrants at $3.75 expiring in 5 years.
Medicus Pharma signs share exchange agreement to acquire Antev Limited
Agreement to acquire all Antev Shares; Antev becomes wholly-owned subsidiary of Medicus.
Medicus will issue 2,666,600 common shares (~17% of outstanding) to acquire all Antev shares on a fully diluted basis.
Medicus Pharma appoints Andrew Smith COO; Phase 2 BCC trial randomized >50 of 90 patients
Andrew Smith appointed COO effective June 30, 2025; base salary $325K, 100k stock options at $2.60 vesting quarterly over 5 years.
Medicus Pharma dismisses EisnerAmper, engages KPMG as auditor
Dismissed EisnerAmper on June 3, 2025; engaged KPMG on June 4, 2025.
Medicus Pharma prices $7M public offering of 2.26M units at $3.10/unit; closes June 2
Gross proceeds $7,006,000 from 2,260,000 units at $3.10/unit; each unit = 1 common share + 1 warrant.
On June 23, 2025, Medicus Pharma Ltd. (the "Company") announced the appointment of Andrew Smith, age 57, to serve as the Company's Chief Operating Officer ("COO").
Max materiality 0.75 · Median 0.60 · Most common event other_material